KR900700124A - Therapeutic Compositions of IL-2 and DTIC for Treatment of Melanoma - Google Patents

Therapeutic Compositions of IL-2 and DTIC for Treatment of Melanoma

Info

Publication number
KR900700124A
KR900700124A KR1019890702190A KR890702190A KR900700124A KR 900700124 A KR900700124 A KR 900700124A KR 1019890702190 A KR1019890702190 A KR 1019890702190A KR 890702190 A KR890702190 A KR 890702190A KR 900700124 A KR900700124 A KR 900700124A
Authority
KR
South Korea
Prior art keywords
composition
dtic
ala
mutein
des
Prior art date
Application number
KR1019890702190A
Other languages
Korean (ko)
Inventor
엠. 페러다이스 캐롤린
씨. 브래들리 에드워드
Original Assignee
알버트 피. 할루인
세투스 코포레이션
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 알버트 피. 할루인, 세투스 코포레이션 filed Critical 알버트 피. 할루인
Publication of KR900700124A publication Critical patent/KR900700124A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2013—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

내용 없음No content

Description

흑색종 치료용 IL-2 및 DTIC의 치료 조성물Therapeutic Compositions of IL-2 and DTIC for Treatment of Melanoma

본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음As this is a public information case, the full text was not included.

Claims (17)

사람의 흑색종 치료에 유용한 조성물을 제조하기 위한 상승적 유효량의 IL-2 및 DTIC의 용도.Use of synergistically effective amounts of IL-2 and DTIC to prepare compositions useful for the treatment of melanoma in humans. 제1항에 있어서, IL-2가 실질적으로 천연 포유류 IL-2의 아미노산 서열을 갖는 조성물.The composition of claim 1, wherein IL-2 has substantially the amino acid sequence of native mammalian IL-2. 제1항에 있어서, IL-2 및 DTIC가 정맥 주입에 의한 비경구 투여용을 제형화된 조성물.The composition of claim 1, wherein the IL-2 and DTIC are formulated for parenteral administration by intravenous infusion. 제3항에 있어서, DTIC의 투여가 IL-2의 투여에 선행하는 조성물.The composition of claim 3, wherein administration of DTIC precedes administration of IL-2. 제3항에 있어서, IL-2투여가 DTIC의 투여에 선행하는 조성물.4. The composition of claim 3, wherein the administration of IL-2 precedes the administration of DTIC. 제3항에 있어서, IL-2 및 DTIC가 동시에 투여되는 조성물.The composition of claim 3, wherein IL-2 and DTIC are administered simultaneously. 제3항, 제4항, 제5항 및 제6항 중의 어느 한 항에 있어서, IL-2의 투여량이 1주당 약5내지 10㎎/㎡이고 DTIC의 투여량이 1주당 약 750내지 1300㎎/㎡인 조성물.The method of any one of claims 3, 4, 5, and 6, wherein the dosage of IL-2 is about 5-10 mg / m2 per week and the dosage of DTIC is about 750-1300 mg / week. M 2. 제4항, 제5항 및 제6항 중의 어느 한항에 있어서, 연속적인 치료학적 주기당 IL-2의 증가 용량을 투여하는 조성물.The composition of any one of claims 4, 5 and 6, wherein an increased dose of IL-2 is administered per continuous therapeutic cycle. 제5항에 있어서, IL-2를 1주당 약 5내지 10㎎/㎡으로 정맥 주입시켜 투여하고, 치료학적 주기의 2주를 반복한 다음, DTIC를 약 1.0g/㎡으로 치료학적 주기의 3주 동안 정맥 주입시켜 투여하는 조성물.6. The method of claim 5, wherein IL-2 is administered intravenously at about 5 to 10 mg / m 2 per week, followed by two weeks of therapeutic cycle followed by DTIC at about 1.0 g / m 2 Composition administered by intravenous infusion for a week. 제6항에 있어서, DTIC를 약 200내지 250㎎/㎡/일로 5일 동안, IL-2를 약 0.5내지 2㎎/㎡/일로 5일동안 정맥 주입시켜 투여하고, 계속해서 치료학적 주기의 2주를 반복하는 조성물.The method of claim 6, wherein DTIC is administered intravenously for 5 days at about 200 to 250 mg / m 2 / day, IL-2 at about 0.5 to 2 mg / m 2 / day for 5 days, followed by two therapeutic cycles. Composition repeating the week. 제2항에 있어서, IL-2가 실질적으로 천연 사람 IL-2의 아미노산 서열을 갖고, 재조합 DNA기술로 생산되는 조성물.The composition of claim 2, wherein IL-2 has substantially the amino acid sequence of natural human IL-2 and is produced by recombinant DNA technology. 제11항에 있어서, IL-2가 뮤테인인 조성물.The composition of claim 11, wherein IL-2 is a mutein. 제12항에 있어서, 뮤테인이, 단독으로 또는 혼합하여, 완전한 천연 사람 서열에 따라 번호를 붙인 125위치에서 세린 또는 알라닌 잔기를 갖고, 1위치에는 알라닌 잔기가 없으며, 104위치에서 세린 또는 알라닌 잔기를 갖는 조성물.The mutein of claim 12, wherein the mutein, alone or in combination, has a serine or alanine residue at position 125 numbered according to the fully native human sequence, no alanine residue at position 1, and a serine or alanine residue at position 104 Having a composition. 제12항 또는 제13항에 있어서, 뮤테인이 des-ala, IL-2, des-ala1ala104IL-2, des-ala1ala104ser125IL-2, des-ala1ser125IL-2, ala104IL-2, ser125IL-2, 또는 ala104ser125IL-2인 조성물.The method according to claim 12 or 13, wherein the mutein is des-ala, IL-2, des-ala 1 ala 104 IL-2, des-ala 1 ala 104 ser 125 IL-2, des-ala 1 ser 125 IL -2, ala 104 IL-2, ser 125 IL-2, or ala 104 ser 125 IL-2. 제14항에 있어서, 뮤테인이 des-ala1ser125IL-2인 조성물.The composition of claim 14, wherein the mutein is des-ala 1 ser 125 IL-2. 제1항에 있어서, IL-2가 이의 용해도 및 순환 반감기를 증가시키기 위해 화학적으로 변형된 조성물.The composition of claim 1, wherein IL-2 is chemically modified to increase its solubility and circulatory half-life. 제16항에 있어서, IL-2가 폴리에틸렌 글리콜의 단독 중합체, 폴리프롤린, 헤파린 단면 또는 풀릴옥시에틸화폴리올(여기서, 폴리에틸렌 글리콜 단독중합체는 비치한 되거나 한쪽 말단이 알킬 그룹에 의해 치환될 수 있다)에 공유결합되어 있는 조성물.18. The method of claim 16, wherein IL-2 is a homopolymer of poly ethylene glycol, polyproline, heparin cross-section or pullyloxyethylated polyol, wherein the polyethylene glycol homopolymer may be provided or one end may be substituted by an alkyl group. A composition covalently bonded to. ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.※ Note: The disclosure is based on the initial application.
KR1019890702190A 1988-03-28 1989-03-24 Therapeutic Compositions of IL-2 and DTIC for Treatment of Melanoma KR900700124A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US174,000 1988-03-28
US07/174,000 US4999339A (en) 1988-03-28 1988-03-28 Combination therapy of IL-2 and DTIC for the treatment of melanoma
PCT/US1989/001236 WO1989009062A1 (en) 1988-03-28 1989-03-24 Combination therapy of il-2 and dtic for the treatment of melanoma

Publications (1)

Publication Number Publication Date
KR900700124A true KR900700124A (en) 1990-08-11

Family

ID=22634400

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019890702190A KR900700124A (en) 1988-03-28 1989-03-24 Therapeutic Compositions of IL-2 and DTIC for Treatment of Melanoma

Country Status (8)

Country Link
US (1) US4999339A (en)
EP (1) EP0422010A1 (en)
JP (1) JPH03503647A (en)
KR (1) KR900700124A (en)
AU (1) AU3427389A (en)
IL (1) IL89750A0 (en)
WO (1) WO1989009062A1 (en)
ZA (1) ZA892275B (en)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2686899B1 (en) * 1992-01-31 1995-09-01 Rhone Poulenc Rorer Sa NOVEL BIOLOGICALLY ACTIVE POLYPEPTIDES, THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM.
US5229109A (en) * 1992-04-14 1993-07-20 Board Of Regents, The University Of Texas System Low toxicity interleukin-2 analogues for use in immunotherapy
US20050100991A1 (en) * 2001-04-12 2005-05-12 Human Genome Sciences, Inc. Albumin fusion proteins
US6926898B2 (en) * 2000-04-12 2005-08-09 Human Genome Sciences, Inc. Albumin fusion proteins
CA2446739A1 (en) * 2001-05-25 2002-12-05 Human Genome Sciences, Inc. Chemokine beta-1 fusion proteins
EP1463752A4 (en) * 2001-12-21 2005-07-13 Human Genome Sciences Inc Albumin fusion proteins
ES2500918T3 (en) * 2001-12-21 2014-10-01 Human Genome Sciences, Inc. Albumin and interferon beta fusion proteins
CA2513213C (en) 2003-01-22 2013-07-30 Human Genome Sciences, Inc. Albumin fusion proteins
MXPA06009794A (en) * 2004-02-27 2007-03-15 Antisense Pharma Gmbh Pharmaceutical composition.
US20080227762A1 (en) * 2004-03-02 2008-09-18 Wisconsin Alumni Research Foundation Lupeol anti-tumor agent and uses thereof
US9844582B2 (en) 2012-05-22 2017-12-19 Massachusetts Institute Of Technology Synergistic tumor treatment with extended-PK IL-2 and therapeutic agents
US9758786B2 (en) 2016-02-09 2017-09-12 Autotelic, Llc Compositions and methods for treating pancreatic cancer
AU2018274216A1 (en) 2017-05-24 2019-12-12 Novartis Ag Antibody-cytokine engrafted proteins and methods of use in the treatment of cancer

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4518584A (en) * 1983-04-15 1985-05-21 Cetus Corporation Human recombinant interleukin-2 muteins
AU7189087A (en) * 1986-04-24 1987-10-29 Cetus Corporation Combination therapy using interleukin-2 and glucocorticoid

Also Published As

Publication number Publication date
EP0422010A1 (en) 1991-04-17
IL89750A0 (en) 1989-09-28
AU3427389A (en) 1989-10-16
US4999339A (en) 1991-03-12
JPH03503647A (en) 1991-08-15
ZA892275B (en) 1990-11-28
WO1989009062A1 (en) 1989-10-05

Similar Documents

Publication Publication Date Title
SE8402560D0 (en) PHARMACEUTICAL COMPOSITION
KR900700124A (en) Therapeutic Compositions of IL-2 and DTIC for Treatment of Melanoma
RU94033520A (en) Injected lecithin gel
PH24313A (en) Emulsion composition for administration of sparingly water soluble ionizable hydrophobic drugs
ATE188219T1 (en) PHARMACEUTICAL DIPEPTIDE COMPOSITIONS AND METHODS OF USE.
ATE189228T1 (en) PEPTIDES WITH CYCLIC MAIN CHAINS, THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
TR200002299T2 (en) Epothilon compositions.
BG91270A (en) ANTIVIRAL AND ANTIBACTERIAL AGENT AND METHOD OF ITS USE
PL316942A1 (en) Novel pharmaceutic compositions based on taxoides
SE8802569D0 (en) IMPROVEMENTS IN OR RELATION TO SOMATOSTATINS
EA200200348A1 (en) PHARMACEUTICAL MORTARS LEVOSIMENDANA
ES2055902T3 (en) PHARMACEUTICAL COMPOSITIONS OF PLASMINOGEN ACTIVATING PROTEINS.
ATE134294T1 (en) COMPOSITION WITH PSYLLIUM
ATE211765T1 (en) NEW FAMILY OF PROTEASE INHIBITORS AND OTHER BIOLOGICALLY ACTIVE SUBSTANCES
KR910018038A (en) Use of a human interleukin 2-active containing polypeptide for the manufacture of a pharmaceutical composition for the treatment of primary pleural cancer
IT1204400B (en) PHARMACEUTICAL COMPOSITIONS CONTAINING A CALCITONIN
NO863027D0 (en) PEPTID PREPARATIONS WITH CONTINUOUS DELIVERY.
NO20042100D0 (en) Method for administering a thymosinal alpha 1 peptide
KR870010871A (en) Intraoperative Treatment of Basal Cell Carcinoma by Recombinant Human Alpha Interferon
GB1514049A (en) Cross-linked orgotein
FR2701952B1 (en) New cyclopeptide derivatives of angiopeptin, their preparation process and the pharmaceutical compositions containing them.
KR930012023A (en) Stabilized pharmaceutical compositions of the reduced form of aglycosylated recombinant human IL2 and methods for their preparation
KR900701311A (en) How to treat squamous cell carcinoma by administering recombinant human α-interferon intralesionally
ATE311881T1 (en) STABILIZED MEDICINAL COMPOSITIONS OF OXAPENEM-3-CARBONIC ACIDS BY FREEZE-DRYING WITH PHARMACEUTICAL EXHIBITS
ATE223700T1 (en) NEW INJECTABLE MEDICINAL PREPARATIONS CONTAINING RAMOPLAN

Legal Events

Date Code Title Description
WITN Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid